BECTON, DICKINSON AND COMPANY

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Treating Diabetic Lipohypertrophy With Intensive Education Versus Standard Care

Not Applicable

Terminated

Conditions: Insulin Injections and Lipohypertrophy

Interventions: Behavioral: Intensive Training on Best Insulin Injection Technique
Behavioral: Standard education on injection technique

First Posted Date: 2014-10-22

Last Posted Date: 2021-06-09

Lead Sponsor: Becton, Dickinson and Company

Target Recruit Count: 31

Registration Number: NCT02271594

Locations: 🇬🇧
Ealing Hospital, Middlesex, London, United Kingdom

Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens

Completed

Conditions: Cervical Neoplasms
Human Papillomavirus

Interventions: Device: BD HPV Assay on Viper LT
Procedure: Colposcopy

First Posted Date: 2014-10-20

Last Posted Date: 2021-02-08

Lead Sponsor: Becton, Dickinson and Company

Target Recruit Count: 6730

Registration Number: NCT02267876

Locations: 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Mobile OB/GYN, Mobile, Alabama, United States
🇺🇸
Tidewater Clinical Research, Virginia Beach, Virginia, United States

and more 37 locations

A Pilot Study Evaluating the Safety and Effectiveness of a New Pleural Catheter for the Medical Management of Symptomatic, Recurrent, Malignant Pleural Effusions

Not Applicable

Completed

Conditions: Malignant Pleural Effusions

Interventions: Device: New Indwelling Pleural Catheter

First Posted Date: 2014-08-28

Last Posted Date: 2021-02-01

Lead Sponsor: CareFusion

Target Recruit Count: 10

Registration Number: NCT02227732

Locations: 🇬🇧
Southmead Hospital - Academic Resporatory Unit, Westbury on Severn, Bristol, United Kingdom

Clinical Evaluation of the BD Onclarity™ HPV Assay on the BD Viper™ LT System With Cervical Specimens

Not Applicable

Completed

Conditions: Uterine Cervical Neoplasms

Interventions: Device: BD Onclarity™ HPV assay on BD Viper™ LT
Procedure: Colposcopy

First Posted Date: 2013-09-18

Last Posted Date: 2018-06-12

Lead Sponsor: Becton, Dickinson and Company

Target Recruit Count: 33858

Registration Number: NCT01944722

Locations: 🇺🇸
Center for Women's Health of Lansdale, Lansdale, Pennsylvania, United States
🇺🇸
Reading Health Physicians Network, West Reading, Pennsylvania, United States
🇺🇸
Mobile OB/GYN, Mobile, Alabama, United States

and more 38 locations

Clinical Evaluation of BD NEXT Pen Needle

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1

Interventions: Device: BD NEXT 32G x 4mm pen needle
Device: BD NEXT 31G x 5 mm pen needle
Device: BD NEXT 31G x 8mm pen needle

First Posted Date: 2013-05-13

Last Posted Date: 2017-02-09

Lead Sponsor: Becton, Dickinson and Company

Target Recruit Count: 217

Registration Number: NCT01852136

Locations: 🇺🇸
Physicians Research Center, Toms River, New Jersey, United States
🇺🇸
Mountain Diabetes and Endocrine Center, Asheville, North Carolina, United States
🇺🇸
Holston Medical Group, Kingsport, Tennessee, United States

and more 2 locations

Study of Effectiveness of Smaller Gauge Fenestrated Catheters for Use in IV Contrast Enhanced CT Scans

Not Applicable

Completed

Conditions: Contrast Enhanced Computed Tomography

Interventions: Device: 20GA BD Nexiva Diffusics
Device: 18GA Conventional Catheter

First Posted Date: 2013-01-21

Last Posted Date: 2014-05-02

Lead Sponsor: Becton, Dickinson and Company

Target Recruit Count: 238

Registration Number: NCT01772550

Locations: 🇺🇸
Johns Hopkins Outpatient Center, Baltimore, Maryland, United States

European Clinical Evaluation of the BD HPV Assay on the BD Viper LT System

Completed

Conditions: Uterine Cervical Neoplasms

First Posted Date: 2012-08-23

Last Posted Date: 2014-02-20

Lead Sponsor: Becton, Dickinson and Company

Target Recruit Count: 1365

Registration Number: NCT01671462

Locations: 🇩🇰
Hvidovre Hospital, Hvidovre, Denmark
🇮🇹
European Institute of Oncology, Milan, Italy

Three-day, In-clinic Evaluation of the BD 2nd Generation Continuous Glucose Sensor Device in Type 1 Diabetics

Not Applicable

Completed

Conditions: Diabetes

Interventions: Device: BD CGM without Outer Layer
Device: BD CGM with Outer Layer
Device: Medtronic iPro2 Professional CGM

First Posted Date: 2012-07-20

Last Posted Date: 2021-12-29

Lead Sponsor: Becton, Dickinson and Company

Target Recruit Count: 30

Registration Number: NCT01645696

Locations: 🇨🇦
>LMC Endocrinology Centre, Clinical Research Unit, Toronto, Ontario, Canada

Multi-day (3) In-patient Evaluation of Intradermal Versus Subcutaneous Basal and Bolus Insulin Infusion

Phase 1

Completed

Conditions: Diabetes

Interventions: Device: Intradermal delivery via the BD Research Catheter Set
Device: Subcutaneous delivery via Medtronic Quick-Set

First Posted Date: 2012-03-20

Last Posted Date: 2012-07-26

Lead Sponsor: Becton, Dickinson and Company

Target Recruit Count: 23

Registration Number: NCT01557907

Locations: 🇩🇪
Profil Institut fur Stoffwechselfforschung GmbH, Neuss, Germany

Topical Antimicrobial Effectiveness Testing

Phase 4

Completed

Conditions: Antimicrobial Effectiveness

First Posted Date: 2011-06-06

Last Posted Date: 2023-07-18

Lead Sponsor: CareFusion

Target Recruit Count: 25

Registration Number: NCT01366417

Locations: 🇺🇸
Microbiotest, Sterling, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy